Dr Reddy's crossed Rs.4000 mark on BSE with 86% income from exports, new launches

Dr Reddy's Laboratories (DRL), the second largest pharmaceutical company in India after Sun Pharmaceutical Industries, is surging ahead with strong domestic sales as well as exports to overseas markets with clear focus on research and development, expansion, alliances and new products. After good financial performance in the first quarter ended June 2015 as well as for full year 2014-15, DRL scrip moved up strongly and touched its yearly high level at Rs.4084.95 with full market capitalization of over Rs.68,550 crore on the BSE. With 25.5 per cent equity holding with promoters and 37.8 per cent by foreign institutional investors, DRL share of Rs.5 each is crossed milestone of Rs.4000 on July 31, 2015.

Considering the changing healthcare scenario, DRL has changed its corporate brand identity recently with new logo which is an expression of empathy and dynamism. The new logo keeps patients at the center of everything that DRL does. The objective of the re-branding exercise is to derive a unifying, patient-centric approach, to meet new and daunting challenges that patients are facing.

DRL has posted satisfactory financial performance during the first quarter ended June 2015. Its consolidated net profit went up by 13.7 per cent to Rs.626 crore from Rs.550 crore in the corresponding period of last year. EBITDA improved by 12 per cent to Rs.990 crore. Its consolidated net sales increased by 6.8 per cent to Rs.3,758 crore from Rs.3,518 crore. EPS improved to Rs.36.71 from Rs.32.34 in the last period.

Pantheon buys Italian-based clinical engineering service provider IBSL

Pantheon Holdco Ltd., doing business as the Pantheon Healthcare Group (Pantheon), has acquired Ingegneria Biomedica Santa Lucia S.p.A. (IBSL), a key Italy-based provider of clinical engineering and a large range of biomedical equipment services, from Gruppo Giglio.

Backed by the Permira Funds, the acquisition is part of Pantheon's continued geographic and modality growth strategy, which launched in August 2014 with the acquisition of Asteral Limited and MESA Group Holdings, two leading independent healthcare service companies operating within the European market. The combination created Europe's first integrated multi-vendor healthcare service platform for procuring, commissioning, managing and maintaining biomedical devices and diagnostic imaging equipment within public- and private-sector hospitals and clinics.

IBSL was born in 1997 from the entrepreneurial idea of Sergio and Bruno Giglio's long customer-centric experience with outsourcing options for heating systems. Their biomedical business quickly grew to become one of the leading clinical engineering service providers in Italy, providing direct maintenance to biomedical systems within hospitals and clinics across Italy. In the ensuing years, IBSL integrated further management expertise and technical competences through the acquisition of D&D Med. Com., Ra.se.co, Gidea Alta Tecnologia and Te.Mo.Sa, further strengthening its position in clinical engineering and expanding its reach in the sector of diagnostic imaging equipment and outsourcing services.